

AHL/AO/2024/0611

Date: 30.10.2024

To
The BSE Limited
The Listing Department
25th Floor, Phiroze Jeejeebhoy Tower,
Dalal Street, Mumbai-400 001

Sub: Investor Presentation

Ref: - Scrip Code: 543943

Dear Sir/ Ma'am,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find attached herewith the Investor Presentation of the Company for the half year ended September 30, 2024.


A copy of the same is placed on the website of the Company www.asarfi.in.

You are requested to take note of the above and arrange to bring this to the notice of all concerned.

Thanking you,

Yours faithfully,

For Asarfi Hospital Limited
For Asarfi Hospital Limited


Udai Pratap Singh
Managing Director
DIN: 08453794



Investor Presentation

H1 FY2025



Agenda

➤ *Consolidated Financial Snapshot – H1'FY25*

➤ *Standalone Financial Snapshot – H1'FY25*

➤ *Consolidated Performance Highlights – H1'FY25*

➤ *Standalone Performance Highlights – H1'FY25*

➤ *Asarfi Hospital : At a Glance*

➤ *Operational Highlights – H1'FY25*

➤ *Consolidated Financial Statements – H1'FY25 & Annual*

➤ *Standalone Financial Statements – H1'FY25 & Annual*

➤ *Facilities Overview*

➤ *Competitive Strengths & Key Growth Drivers*

➤ *Vision 2026*

➤ *Board of Directors and Key Managerial Personnel*

Abbreviations

ACI	Asarfi Cancer Institute	ARPOB	Average Revenue Per Occupied Bed
AHL	Asarfi Hospital Ltd	ALOS	Average Length of Stay
BCCL	Bharat Coking Coal Ltd	CAGR	Compound Annual Growth Rate
BSE	Bombay Stock Exchange	EBIT	Earnings Before Interest and Taxes
CCU	Cardiac Care Unit	EBITDA	Earnings Before Interest, Taxes, Depreciation, and Amortization
CT Scan	Computed Tomography Scan	PAT	Profit After Tax
ESIC	Employees' State Insurance Corporation	PBT	Profit Before Tax
ICU	Intensive Care Unit	ROCE	Return on Capital Employed
IPD	Inpatient Department	ROE	Return on Equity
IPO	Initial Public Offering	TTM	Trailing - Twelve Months
MRI	Magnetic Resonance Imaging	USP	Unique Selling Proposition
NICU	Neonatal Intensive Care Unit	Y-o-Y	Year over Year
NABH	National Accreditation Board for Hospitals & Healthcare Providers		
NABL	National Accreditation Board for Testing and Calibration Laboratories		
OPD	Outpatient Department		
PET CT	Positron Emission Tomography Computed Tomography		
SICU	Surgical Intensive Care Unit		
SME	Small and Medium Enterprises		

Financial Snapshot (Consolidated) - H1'FY25

- Consolidated Revenues at ₹ 5,378.4 Lakhs in H1'FY25 vs ₹ 4,031.7 Lakhs in H1'FY24, grew by 33.4% on a Y-o-Y basis.
- Consolidated EBITDA at ₹ 1,152.1 Lakhs in H1'FY25 vs ₹ 809.9 Lakhs in H1'FY24, grew by 42.3% on a Y-o-Y basis.

- Consolidated PBT at ₹ 539.2 Lakhs in H1'FY25 vs ₹ 325.2 Lakhs in H1'FY24, grew by 65.8% on a Y-o-Y basis.
- Consolidated PAT at ₹ 430.3 Lakhs in H1'FY25 vs ₹ 206.9 Lakhs in H1'FY24, grew by 108% on a Y-o-Y basis.

- Consolidated Net Debt at ₹ 2,425.5 Lakhs in H1'FY25 vs ₹ 904.1 Lakhs in H1'FY24.
- Debt-to-Equity Ratio as of H1'FY25 stood at 0.59 compared to 0.47 as of H1'FY24.
- Consolidated ROCE (TTM) for H1'FY25 stood at 8.98% vs 8.18% in H1'FY24.

Financial Snapshot (Standalone) - H1'FY25


- *Standalone Revenues at ₹ 5,378.4 Lakhs in H1'FY25 vs ₹ 4,031.7 Lakhs in H1'FY24, grew by 33.4% on a Y-o-Y basis.*
- *Standalone EBITDA at ₹ 1,162.4 Lakhs in H1'FY25 vs ₹ 809.9 Lakhs in H1'FY24, grew by 43.5% on a Y-o-Y basis.*

- *Standalone PBT at ₹ 552.0 Lakhs in H1'FY25 vs ₹ 325.2 Lakhs in H1'FY24, grew by 69.7% on a Y-o-Y basis.*
- *Standalone PAT at ₹ 443.2 Lakhs in H1'FY25 vs ₹ 206.9 Lakhs in H1'FY24, grew by 114% on a Y-o-Y basis.*

- *Standalone Net Debt at ₹ 2,433.3 Lakhs in H1'FY25 vs ₹ 904.1 Lakhs in H1'FY24.*
- *Debt-to-Equity Ratio as of H1'FY25 stood at 0.59 compared to 0.47 as of H1'FY24.*
- *Standalone ROCE (TTM) for H1'FY25 stood at 9.11% vs 8.18% in H1'FY24.*


Performance Highlights (Consolidated) – H1'FY25

Revenues (₹ in Lakhs)




■ Total Income

EBITDA (₹ in Lakhs)




■ EBITDA ■ EBITDA Margin %

EBIT (₹ in Lakhs)



■ EBIT ■ EBIT Margin %


Profit after Taxes (₹ in Lakhs)




■ PAT ■ PAT Margin %

Performance Highlights (Standalone) – H1'FY25


Revenues (₹ in Lakhs)




EBITDA (₹ in Lakhs)



EBIT (₹ in Lakhs)



Profit after Taxes (₹ in Lakhs)



Asarfi Hospital : At a Glance

Asarfi Hospital Limited (AHL), Established in 2008, is a key multi-specialty tertiary healthcare service provider in the Dhanbad Area which was founded and managed by first-generation entrepreneurs Mr. Harendra Singh, Mr. Nayan Prakash Singh, and Mr. Udai Pratap Singh.

- AHL operates two hospitals across Dhanbad region, catering to a dense population of ~16.5 Lakhs, with a total bed capacity of 300 beds, comprising 250 beds at its Super Multi-Specialty Hospital in Baramuri, which is operating at an average occupancy rate of 60.0% and 50 beds at its New Cancer Hospital in Ranguni, operating at an average occupancy rate of 57.0% during H1'FY25.

- Since its inception in 2008, AHL has established a remarkable track record of clinical and operational expertise, spanning over 16 years.
- The Hospital boasts a full-fledged High Dependency Unit, Emergency Department, Outpatient Consultation, CCU, ICU, NICU, SICU, Labor Room, Cardiac Unit etc.

- The Diagnostic Centre features advanced laboratory and imaging equipment like the Open XRay, Ultrasound, CT scan and MRI.
- Robust team of medical professionals, comprising over 70 doctors, including 62 full-time in-house doctors and 10+ visiting doctors.

- Additionally, the hospital has a dedicated team of over 300 nursing staff and more than 400 supporting staff members.
- Company has earned prestigious accreditations from the NABH and NABL.



23+

Specialised
Facilities



60+

Full-time Doctors



300 Beds

16+ Years of
experience

Departments and Facilities



Cardiology



Neurosciences



General medicine



Paediatrics & Neonatology



Obstetrics & Gynaecology



General Surgery



Gastroenterology



Orthopaedics




Burn & Plastic Surgery



Oncology



Nephrology



Urology



Ophthalmology



ENT



Day Care services



Dental Sciences



Physiotherapy



Emergency



Nutrition & Dietetics



Anaesthesiology & Critical Care



Radiology



Pulmonology



Pain Management

Asarfi's New Cancer Institute



50

Operational
Beds



1/3 Cancer Hospital

In the state of
Jharkhand


- With a mission to provide comprehensive, state-of-the-art cancer care with a holistic approach that encompasses medical expertise, emotional support, and cutting-edge technology, Asarfi Hospital laid down the foundations for the construction of its new Cancer Institute in Ranguni, Dhanbad, which is now the first dedicated comprehensive cancer care hospital in a 200km radius of Dhanbad and just 1 out of 3 in the state of Jharkhand.
- Asarfi's Cancer Institute started operating from 2024 and is well equipped with Jharkhand's first and most advanced Linear Accelerator radiation machine-The Varian True Beam to offer the most precise radiation therapy treatment. The Centre also has a Siemens 64 slice PET CT machine and is equipped with all modern facilities to do every type of PET CT to diagnose cancer.
- The center is the front runner in providing organ specific Cancer Care in the state of Jharkhand and has a functional multidisciplinary tumour board.
- Currently, all departments of Oncology including Medical Oncology, Radiation Oncology, Surgical Oncology and Nuclear Medicine are functional at the Cancer Institute and many more facilities will be added in the coming years.
- Currently operating with 50 beds across 2 floors, operating at an average occupancy rate of 57.0% in H1'FY25, which is expected to reach 60% by the end of FY25.
- The Cancer Institute has Infrastructure in place to increase bed capacity to 150 beds with an additional capex of Rs. 2-3 crores.
- Additionally, the hospital has approval for building up to 7 floors, enabling future expansion based on demand.

Operational Highlights - H1'FY25 (1/2)


- ❑ For the half-year ended September 2024, AHL reported revenue of Rs. 4,675.1 lakhs from its Super Multi-Specialty Hospital (Baramuri), Rs. 613.0 lakhs from its cancer hospital (Ranguni), Rs. 72.7 lakhs from SRT Labs and 16.9 lakhs from Nursing courses, total revenue of Rs. 5,378 lakhs.
 - ❑ Patients served during H1'FY25 is 60,305 vs 48,163 patients in H1'FY24, grew by 25.2% YoY.
 - ❑ During H1'FY25, Cardiology & General medicine revenues grew by 14.8% & 37.5% on a YoY basis, respectively. Whereas, Neurosciences & Pediatrics revenue fell by (15.2%) and (4.6%) respectively. Oncology revenue grew by 480% YoY and General Surgery is up by 55.8%.
- ❑ Average Revenue per operating bed (ARPOB) during H1'FY25 is at Rs. 19,524 compared to Rs. 18,055 in H1'FY24, grew by 2.2% YoY.
 - ❑ IPD Revenues during H1'FY25 is up by 29.9% y-o-y whereas OPD revenues grew by 38.3% y-o-y.
 - ❑ IPD Volume during H1'FY25 is up by 32.0% y-o-y whereas OPD volume grew by 24.5% y-o-y.
- ❑ As of September 24, AHL had trade receivables amounting to Rs. 2,804.2 lakhs, comprising Rs. 877.8 lakhs from ESI, Rs. 688.1 lakhs from Railway, Rs. 401.8 lakhs from BCCL and its associated companies, Rs. 146.6 Lakhs from ECHS and remaining from Others. The average collection period for the debtors stands at approximately 105 days, or 3.5 months, which is consistent with the industry standard for hospitals.
- ❑ AHL improved its occupancy rate to 60% during H1'FY25 compared to 58% during H1'FY24.
 - ❑ AHL has invested a total of approximately Rs. 7,500 Lakhs in its cancer hospital project, funded by a combination of IPO proceeds and other sources.

Operational Highlights – H1'FY25 (2/2)


IPD-OPD Volumes




IPD-OPD Revenues (In Rs Lakhs)




ARPOB / Day (In Rs.)





Bed Capacity & Occupancy rate %



Revenue Mix H1'FY25 Vs H1'FY24 (1/2)



Revenue Mix H1'FY25 Vs H1'FY24 (2/2)



Profit & Loss Account (Consolidated) – H1'FY25

(₹ in Lakhs)

Particulars	FY24	H1FY24	H2FY24	H1FY25
Revenue	8,440.0	4,031.7	4,408.3	5,378.4
Other Income	167.0	87.9	79.1	180.6
Total Income	8,607.1	4,119.6	4,487.4	5,558.9
Yoy Revenue Growth %	19.4%	-	-	33.4%
Cost of Goods Sold	(2,032.1)	(954.0)	(1,078.0)	(1318.3)
Gross Profit	6,408.0	3,077.7	3,330.3	4,060.1
Gross Profit Margin %	75.9%	76.3%	75.5%	75.5%
Employee Cost	(1,413.1)	(647.1)	(766.1)	(818.7)
Other Expenses	(3,389.8)	(1,620.7)	(1,769.0)	(2,089.3)
EBITDA	1,605.1	809.9	795.2	1,152.1
Yoy EBITDA Growth %	16.6%	-	-	42.3%
EBITDA Margin %	19.0%	20.1%	18.0%	21.4%
Depreciation Exp.	(878.8)	(439.7)	(439.1)	(637.7)
Depreciation as a % of Revenues	10%	11%	10%	12%
EBIT	893.4	458.1	435.2	695.0
YoY EBIT Growth %	(26.9)%	-	-	51.7%
EBIT Margin %	10.4%	11.1%	9.7%	12.5%
Finance Cost	(269.2)	(132.9)	(136.4)	(155.8)
PBT	624.1	325.2	298.9	539.2
Effective Tax Rate (%)	33.3%	36.4%	30.0%	20.2%
PAT	416.2	206.9	209.3	430.3
YoY Growth %	(48.0)%	-	-	104%
PAT Margin %	4.8%	5.0%	4.7%	7.7%

- H1'FY25 Revenues showed a robust growth of 33.4% on a YoY basis, standing at Rs. 5,378.4 lakhs as against 4,031.7 lakhs in H1'FY24.
- H1'FY25 Profit after taxes (PAT) grew by 104% to Rs. 430.3 lakhs as against Rs. 206.9 Lakhs in H1'FY24.
- H1'FY25 EBITDA grew by 42.3% on a YoY basis to Rs. 1,152.1 Lakhs as against 809.9 Lakhs in H1'FY24, whereas EBITDA margin improved to 21.4% as against 20.1% during the same period last year.

Profit & Loss Account (Standalone) – H1'FY25

(₹ in Lakhs)

Particulars	FY22	FY23	FY24	H1FY24	H2FY24	H1FY25
Revenue	6,519.0	7,070.0	8,440.0	4,031.7	4,408.3	5,378.4
Other Income	98.2	233.0	167.0	87.9	79.1	180.6
Total Income	6,617.2	7,303.0	8,607.1	4,119.6	4,487.4	5,558.9
Yoy Revenue Growth %	20.5%	8.5%	19.4%	-	-	33.4%
Cost of Goods Sold	(2,567.0)	(2,001.7)	(2,032.1)	(954.0)	(1,078.0)	(1,318.3)
Gross Profit	3,952.0	5,068.3	6,408.0	3,077.7	3,330.3	4,060.1
Gross Profit Margin %	60.6%	71.7%	75.9%	76.3%	75.5%	75.5%
Employee Cost	(876.6)	(1,123.1)	(1,413.1)	(647.1)	(766.1)	(818.7)
Other Expenses	(2,000.0)	(2,568.3)	(3,385.2)	(1,620.7)	(1,764.5)	(2,079.0)
EBITDA	1,075.4	1,376.9	1,609.7	809.9	799.8	1,162.4
Yoy EBITDA Growth %	33.7%	28.0%	16.9%	-	-	43.5%
EBITDA Margin %	16.5%	19.5%	19.1%	20.1%	18.1%	21.6%
Depreciation Exp.	(334.7)	(387.4)	(878.3)	(439.7)	(438.6)	(635.1)
Depreciation as a % of Revenues	5.1%	5.5%	10.4%	10.9%	9.9%	11.8%
EBIT	839.0	1,222.6	898.4	458.1	440.3	707.9
YoY EBIT Growth %	63.5%	45.7%	(26.5)%	-	-	54.5%
EBIT Margin %	12.7%	16.7%	10.4%	11.1%	9.8%	12.7%
Finance Cost	(70.2)	(133.9)	(269.2)	(132.9)	(136.4)	(155.8)
PBT	768.8	1,088.7	629.2	325.2	303.9	552.0
Effective Tax Rate (%)	25.9%	26.4%	33.1%	36.4%	29.5%	19.7%
PAT	570.0	801.0	421.2	206.9	214.4	443.2
YoY Growth %	61.1%	40.5%	(47.4)%	-	-	114%
PAT Margin %	8.6%	11.0%	4.9%	5.0%	4.8%	8.0%

- H1'FY25 Revenues showed a robust growth of 33.4% on a YoY basis, standing at Rs. 5,378.4 lakhs as against 4,031.7 lakhs in H1'FY24.
- H1'FY25 Profit after taxes (PAT) grew by 114% to Rs. 443.2 lakhs as against Rs. 206.9 Lakhs in H1'FY24.
- H1'FY25 EBITDA grew by 43.5% on a YoY basis to Rs. 1,162.4 Lakhs as against 809.9 Lakhs in H1'FY24, whereas EBITDA margin improved to 21.6% as against 20.1% during the same period last year.

Balance Sheet (Consolidated) – H1'FY25

(₹ in Lakhs)

Particulars	FY24	H1'FY24	H1'FY25
Total Shareholders Funds	7,040.7	6,802.2	7,451.8
Total Non-Current Liabilities (Long-term Borrowings & Other NCL)	4,220.2	4,405.0	5,138.7
Total Sources of Funds	11,260.9	11,207.2	12,590.5
Total Non-Current Assets (PP&E and Other NCA)	10,733.6	9,461.1	10,342.7
Net Working Capital	(1,232.3)	(551.1)	280.9
Cash & Cash Equivalents	1759.6	2,297.2	1,966.9
Total Application of Funds	11,260.9	11,207.2	12,590.5

- Debt to Equity Ratio as of H1'FY25 stood at 0.59 compared 0.47 in H1'FY24.
- Current Ratio as of H1'FY25 stood at 1.70 compared to 1.40 in H1'FY24.
- Inventory Turnover Ratio as of H1'FY25 stood at 12.31 compared to 11.42 in H1'FY24.
- ROCE as of H1'FY25 stood at 8.98% compared to 8.18% in H1'FY24.

Standalone Balance Sheet – H1'FY25

(₹ in Lakhs)

Particulars	FY22	FY23	FY24	H1'FY24	H1'FY25
Total Shareholders Funds	2,262.8	4,185.6	7,045.8	6,802.2	7,469.7
Total Non-Current Liabilities (Long-term Borrowings & Other NCL)	2,531.2	3,199.4	4,220.2	4,405.0	5,138.7
Total Sources of Funds	4,794.0	7,385.0	11,265.9	11,207.2	12,608.4
Total Non-Current Assets (PP&E and Other NCA)	4,062.0	6,202.1	10,742.6	9,461.1	10,373.0
Net Working Capital	(640.1)	331.1	(1,226.2)	(551.1)	276.3
Cash & Cash Equivalents	1,372.1	851.9	1,749.5	2,297.2	1,959.1
Total Application of Funds	4,793.9	7,385.1	11,265.9	11,207.2	12,608.4

- Debt to Equity Ratio as of H1'FY25 stood at 0.59 compared 0.47 in H1'FY24.
- Current Ratio as of H1'FY25 stood at 1.69 compared to 1.40 in H1'FY24.
- Inventory Turnover Ratio as of H1'FY25 stood at 12.31 compared to 11.42 in H1'FY24.
- ROCE as of H1'FY25 stood at 9.11% compared to 8.18% in H1'FY24.

Facilities Overview (1/3)



Asarfi Hospital, Baramuri, Dhanbad

Asarfi Multi-Speciality Hospital, Baramuri, Dhanbad, Jharkhand.

- **Location:** Situated on the Main Highway, 6 km from Dhanbad Railway Station.
- **Building:** 4 blocks, 6 floors, constructed area >1 Lacs sq. ft., land area 92 decimals
- **Specialty:** Cardiology and Neurology contribute ~50% of revenue.
- **Bed capacity:** 250 beds, with potential expansion up to 150 beds with space modification.
- **Pharmacy:** Contributes 25% of revenue, a significant portion compared to other hospitals.

	ARPOB	No. of Beds	Occupancy	ALOS
H1'FY25	19,958.2	250	60.0%	4.0
H1'FY24	18055.2	250	58.0%	4.0

Facilities Overview (2/3)



**Asarfi Cancer Institute, Ranguni,
Dhanbad**

New Cancer Institute, Ranguni, Dhanbad, JHARKHAND.

- **Land Details:** Leased 9.55 acres (5,06,000 Sq. Ft) of land from Jharkhand Industrial Area Development Authority (JIADA) for 30 years.
 - **Bed Capacity:** 50 beds across 2 floors, operating at 25% occupancy.
 - **Occupancy level:** Expected to attain 75% Occupancy level by FY25
- **Expansion Potential:** Infrastructure in place to increase bed capacity to 150 beds with an additional capex of Rs. 2-3 crores.
 - Approval for building up to 7 floors, enabling future expansion based on demand.
- **USP:** AHL is the only dedicated comprehensive Cancer care hospital in a 200 km radius of Dhanbad.
 - Equipped with advanced machines (brands like Varian, Siemens, GE, Allenger). Experienced and renowned surgeons in the region.

	ARPOB	No. of Beds	Occupancy	ALOS
H1'FY25	16,748.6	50	57.0%	5.0
H1'FY24	N / A	N / A	N / A	N / A

Facilities Overview (3/3)




Land for Research Institute, Ranchi

Research Institute for Medical and Non-Medical Courses, Ranchi, Jharkhand.

- **Location:** 4 km from Ranchi Airport, with solid road infrastructure and surrounded by HEC India.
- **Land Details:** 5.6 acres (22,662 sq. mtrs) of land acquired at a cost of Rs 13.2 crores (registry pending). As per management, Land value appreciated to ~Rs 65 crores.
- **Plan:** to start medical and non-medical research management courses at the Research institute by the FY28.

Our Journey




IPO Proceeds and Utilisation



₹ 7.08 allocated for General Corporate purposes



₹ 7.65 allocated as Capex for Research Institute in Ranchi



₹ 12.21 allocated as Capex for Cancer Hospital in Dhanbad

- ✓ The IPO was entirely a fresh issue of 51.8 lakh shares.
- ✓ The shares got listed on BSE SME at ₹ 98.8 on July 26, 2023 at a staggering 90% premium over its issue price of ₹ 52.


Competitive Strengths



Advanced high-end medical equipment and Technology

- ✓ Equipped with cutting-edge laboratory and imaging equipment, including Open X-Ray, Ultrasound, CT Scans, MRI and PET Scan with prestigious certifications from NABH and NABL.

Regional Advantage



- ✓ The only cancer hospital in Dhanbad and one of just three in Jharkhand, it serves a significantly underserved region with a population of approximately 16.5 lakh people.



Track record of stable operating and financial performance

- ✓ Stable operating and financial performance and growth over past three fiscal years with focus on revenue growth, margins and outsourcing non-core activities.

Experienced & highly qualified team of medical professionals



- ✓ AHL boasts a robust team of medical professionals, comprising over 70 doctors, including 62 full-time in-house doctors and ~10+ visiting doctors. Hospital also has a dedicated team of over 300 nursing staff and more than 400 supporting staff members.

Expansion Plans



- ❑ Introduction of an IVF vertical in the existing hospital, catering to reproductive health needs.



- ❑ Establishment of a Bone Marrow Transplant unit in the cancer hospital, enhancing oncology care capabilities.




- ❑ Launch of educational courses in law, BCA, and medical fields, leveraging existing infrastructure. A new building is being constructed on approximately 2 acres of land, out of the 12 acres allocated for the cancer hospital.




- ❑ Strategic capacity expansion: Increasing bed capacity in the existing Baramuri facility from 250 to 350, contingent upon demand. - Enhancing bed capacity in the cancer hospital from 50 to 150 by FY26.

Key Growth Drivers



Vision 2026

VISION 2026



Board of Directors & Key Managerial Personnel



Harendra Singh

Promoter & CFO

- A visionary entrepreneur inspired by the Company's Purpose—Health for All.
- He believes that good leaders must be passionate about learning, and he is focused to develop world-class organizations.
- Graduated from AN College, Patna with a Bachelor of Science degree in Electronics. He subsequently completed his MBA from LBSIM, New Delhi in 1999.



Udai Pratap Singh

Promoter and MD

- Started his career in 2017, he is a process and system driven person and believes strongly in "quality" and "efficiency" in healthcare.
- He graduated from PES Institute of Technology and pursued his master's degree from University of Cincinnati, USA.



Sukanti Kumar Das

Non- Executive Director

- Renowned Consultant Gynaecologist and brings with him over 35 years' experience.
- He was the Deputy CMO in Central Hospital, Dhanbad and the Chairman of FOGSI at Dhanbad, Jharkhand.
- Dr. Das graduated from R.G. Kar Medical College in Calcutta and subsequently completed DGO, MD from PGI Chandigarh.



Madhuri Singh

Executive Director

- Directs the Quality, Housekeeping and Diet n Nutrition for the hospital.
- She has excellent cleanliness skills and is experienced in the field for over 10 years.



Gopal Singh

Executive Director

- Experienced individual with a strong background in civil construction and procurement.

Disclosure and Contact Details

Certain matters discussed in this presentation may contain statements regarding the company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements do not guarantee future performance and are subject to various known and unknown risks, uncertainties, and assumptions that are inherently difficult to predict. These risks and uncertainties encompass, but are not limited to, the performance of the economy, industry trends, competitive landscape, the company's ability to successfully execute its strategy, technological advancements, changes in market preferences, and exposure to market risks, as well as other potential risks. The company's actual results, levels of activity, performance, or achievements may differ materially and adversely from the results expressed or implied in this presentation. The company assumes no obligation to update any forward-looking information contained in this presentation. Any forward-looking statements and projections made by third parties included in this presentation are not endorsed or adopted by the company, and the company disclaims any responsibility for such third-party statements and projections. You are cautioned not to place undue reliance on these forward-looking statements, which are based on the current views and assumptions of the Company's management regarding future events.

For further information, please contact:

Mr. Udai Pratap Singh

Managing Director (MD)

Contact No. - 9608833708

Email Id - cs@asarfihospital.com